Godavari Drugs revenue slips to ₹105.81 cr in FY26

Tipsheet Editorial — Wed, 27 May 2026 17:02:36 GMT

The nano-cap pharmaceutical firm reported a modest annual decline in both revenue and profit, though Q4 showed sequential growth.

What’s new

FY26 revenue dropped to ₹105.81 cr from ₹113.35 cr in FY25.
Full-year net profit fell to ₹4.09 cr from ₹4.38 cr.
Q4 standalone revenue reached ₹33.16 cr, showing sequential and year-on-year improvement.

Why it matters

The results are routine and lack any material surprises. For a nano-cap company, the slight contraction in annual profitability confirms a period of stagnant performance rather than a shift in trajectory.

What we’re watching

Whether Q4's sequential revenue improvement continues into FY27.
Updates on the use of preferential issue proceeds.
Any future guidance regarding margin pressures.

The full read

Godavari Drugs closed FY26 with ₹105.81 crore in revenue, a modest decline from the ₹113.35 crore recorded in FY25. Net profit followed a similar path, slipping to ₹4.09 crore from ₹4.38 crore. While the annual figures reflect a slight contraction, the company did report a brighter spot in the final quarter, with standalone revenue hitting ₹33.16 crore. This figure marks both a sequential and year-on-year improvement. Beyond the financials, the filing is strictly procedural, covering standard items like auditor appointments and the upcoming AGM. There were no profit warnings, guidance updates, or unexpected strategic shifts. For investors, this is a routine disclosure that confirms the company's current operational baseline. The numbers contain no surprises.

Primary source: BSE · NSE

Godavari Drugs reports flat FY26 results as revenue slips to ₹105.81 cr

Tipsheet Editorial — Wed, 27 May 2026 16:57:24 GMT

The nano-cap pharmaceutical company saw annual revenue and profit decline slightly, though Q4 standalone revenue showed improvement.

What’s new

FY26 revenue fell to ₹105.81 cr from ₹113.35 cr in FY25.
Net profit for the year dropped to ₹4.09 cr from ₹4.38 cr.
Q4 standalone revenue reached ₹33.16 cr, marking a sequential and year-on-year rise.

Why it matters

The results show a period of stagnation for the company. While the Q4 revenue uptick provides a minor positive, the annual decline in both top and bottom lines confirms a lack of growth momentum.

What we’re watching

Whether the Q4 revenue improvement signals a sustained recovery in FY27.
Updates on the utilization of preferential issue proceeds.
Management commentary on margin pressures affecting annual profitability.

The full read

Godavari Drugs closed FY26 with a modest decline in its financial metrics. Annual revenue slipped to ₹105.81 crore from ₹113.35 crore in the previous year, while net profit fell to ₹4.09 crore from ₹4.38 crore. Despite the annual contraction, the company recorded ₹33.16 crore in standalone revenue for Q4, showing both sequential and year-on-year growth. The filing remains a routine disclosure, covering standard board outcomes such as the appointment of cost auditors and the planning of the upcoming AGM. There were no surprises in the numbers, nor were there any shifts in guidance or strategy. The company also confirmed that its preferential issue proceeds were used as intended. For investors, the results confirm a period of flat performance for the nano-cap firm, with the Q4 revenue uptick serving as the only notable deviation from the broader annual trend.

Primary source: BSE · NSE

Godavari Drugs Ltd. (GODAVARI) — Tipsheet

Godavari Drugs revenue slips to ₹105.81 cr in FY26

What’s new

Why it matters

What we’re watching

The full read

Godavari Drugs reports flat FY26 results as revenue slips to ₹105.81 cr

What’s new

Why it matters

What we’re watching

The full read